-
公开(公告)号：US12023313B2
公开(公告)日：2024-07-02
申请号：US17156894
申请日：2021-01-25
发明人： Madusha Peiris , Ashley Blackshaw
摘要： The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for use in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.
-
2.发明公开公开(公告)号：US20240058594A1
公开(公告)日：2024-02-22
申请号：US18471638
申请日：2023-09-21
IPC分类号： A61M60/422 , A61M60/148 , A61M60/274 , A61M60/876 , A61M60/531 , A61M60/546 , A61M60/30 , A61M60/139 , A61M60/237 , A61M60/221 , A61M60/232
CPC分类号： A61M60/422 , A61M60/148 , A61M60/274 , A61M60/876 , A61M60/531 , A61M60/546 , A61M60/30 , A61M60/139 , A61M60/237 , A61M60/221 , A61M60/232 , A61F2/06
摘要： Mechanical circulatory supports configured to operate in series with the native heart are disclosed. In an embodiment, a centrifugal pump is used. In an embodiment, inlet and outlet ports are connected into the aorta and blood flow is diverted through a lumen and a centrifugal pump between the inlet and outlet ports. The supports may create a pressure rise between about 40-80 mmHg, and maintain a flow rate of about 5 L/min. The support may be configured to be inserted in a collinear manner with the descending aorta. The support may be optimized to replicate naturally occurring vortex formation within the aorta. Diffusers of different dimensions and configurations, such as helical configuration, and/or the orientation of installation may be used to optimize vortex formation. The support may use an impeller which is electromagnetically suspended, stabilized, and rotated to pump blood.
-
公开(公告)号：US20230393138A1
公开(公告)日：2023-12-07
申请号：US18365369
申请日：2023-08-04
发明人： Tianyu Guo , Lei Xu , Xueying Mao , Yong-Jie Lu
IPC分类号： G01N33/574 , C12N5/078 , C12Q1/6841
CPC分类号： G01N33/57434 , G01N33/574 , C12N5/0644 , C12Q1/6841 , G01N2333/4742 , G01N2333/70557 , G01N2333/70589 , G01N2333/70596 , G01N2800/52
摘要： The present invention provides a method for determining the prognosis of cancer in a subject. The method comprises measuring the amount of megakaryocytes in a sample from the subject. Usually, the sample is a blood sample. The method may also comprise measuring the number of circulating tumour cells (CTCs) in the sample, and in some embodiments a comparison of the number of megakaryocytes and CTCs in the sample. The present invention also provides methods of treatment for cancer in a patient for whom a poor prognosis is predicted using a method of prognosis of the invention.
-
公开(公告)号：US11721317B2
公开(公告)日：2023-08-08
申请号：US16960048
申请日：2018-11-29
发明人： Joshua Reiss , Thomas Vassallo , Adan Benito , Parham Bahadoran
IPC分类号： G10K15/02 , G06F3/16 , H03G3/00 , G09B15/04 , G10H1/00 , G10L13/08 , G06F3/01 , G10H5/02 , A63F13/54 , G11B27/034 , A63F9/24
CPC分类号： G10K15/02 , G06F3/165 , A63F9/24 , A63F13/54 , G06F3/01 , G09B15/04 , G10H1/0025 , G10H5/02 , G10H2210/125 , G10H2220/096 , G10H2250/321 , G10H2250/371 , G10H2250/395 , G10L13/08 , G11B27/034 , H03G3/00
摘要： Disclosed herein is a sound synthesis system for generating a user defined synthesised sound effect, the system comprising: a receiver of user defined inputs for defining a sound effect; a generator of control parameters in dependence on the received user defined inputs; a plurality of sound effect objects, wherein each sound effect object is arranged to generate a different class of sound and each sound effect object comprises a sound synthesis model arranged to generate a sound in dependence on one or more of the control parameters; a plurality of audio effect objects, wherein each audio effect object is arranged to receive a sound from one or more sound effect objects and/or one or more other audio effect objects, process the received sound in dependence on one or more of the control parameters and output the processed sound; a scene creation function arranged to receive sound output from one or more sound effect objects and/or audio effect objects and to generate a synthesised sound effect in dependence on the received sound; and an audio routing function arranged to determine the arrangement of audio effect objects, sound effect objects and scene creation function such that one or more sounds received by the scene creation function are dependent on the audio routing function; wherein the determined arrangement of audio effect objects, sound effect objects and the scene creation function by the audio routing function is dependent on the user defined inputs.
-
公开(公告)号：US20230090069A1
公开(公告)日：2023-03-23
申请号：US17904734
申请日：2021-03-05
申请人： CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES , HUMANITAS MIRASOLE SPA , THE UNIVERSITY OF SUSSEX , KING'S COLLEGE LONDON , QUEEN MARY UNIVERSITY OF LONDON , SORBONNE UNIVERSITE , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS , THE UNIVERSITY OF SHEFFIELD
发明人： Gilbert BENSIMON , Peter Nigel LEIGH , Timothy TREE , Cecilia GARLANDA , Massimo LOCATI , Janine KIRBY , Pamela SHAW , Andrea MALASPINA
IPC分类号： A61K38/20 , A61K31/428 , A61P25/28
摘要： The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU) Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 HI human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.
-
公开(公告)号：US11531036B2
公开(公告)日：2022-12-20
申请号：US16608428
申请日：2018-04-26
发明人： Jesmond Dalli , Romain Alexandre Colas , Patricia Regina Soares De Souza , Mary Elizabeth Walker
IPC分类号： G01N33/92 , G01N33/543 , A01N1/02
摘要： A method, device, computer program and related immunoassay are disclosed for assessing the efficacy of a statin selected from, for example, selected from RvT1 (7,13,20-trihydroxy-8,10,14,16Z,18-docosapentaenoic acid), RvT2 (7,12,13-trihydroxy-8,10,14,16Z,19Z-docosapentaenoic acid), RvT3 (7,8,13-trihydroxy-9,11,14,16Z,19Z-docosapentaenoic acid) and RvT4 (7,13-dihydroxy-8,10,14,16Z,19Z-docosapentaenoic acid), for use in the treatment of an inflammatory condition in an individual patient, which comprises measuring the levels of at least one 13-series resolvin in biological samples obtained from the patient before and after administration of the statin, wherein an increase in the level of the resolvin after administration of the statin is indicative of efficacy of the statin. Also disclosed is a method of storing a biological sample to preserve lipid mediators in the sample comprising placing the sample in an organic solvent and storing the sample at a temperature of ≤−75° C.
-
公开(公告)号：US20220340974A1
公开(公告)日：2022-10-27
申请号：US17764717
申请日：2020-09-30
IPC分类号： C12Q1/6883
摘要： A method for identifying a subject requiring treatment with a biologic therapy for rheumatoid arthritis, the method comprising the steps: (a) determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the one or more biomarkers are selected from Table 1; and (b) comparing the level of the one or more biomarkers to one or more corresponding reference values; wherein the levels of the one or more biomarkers compared to the corresponding reference values are indicative of the requirement for treatment with a biologic therapy for rheumatoid arthritis.
-
公开(公告)号：US11263471B2
公开(公告)日：2022-03-01
申请号：US16482692
申请日：2018-01-29
发明人： Hamit Soyel , Peter McOwan
摘要： The present invention provides a novel algorithm for salience detection based on a dual rail antagonistic structure to predict where people look in images in a free-viewing condition. Furthermore, the proposed algorithm can be effectively applied to both still and moving images in visual media without any parameter tuning in real-time.
-
公开(公告)号：US11058405B2
公开(公告)日：2021-07-13
申请号：US16319058
申请日：2017-06-13
IPC分类号： A61B17/00
摘要： A surgical tool for use in the treatment of anal fistulas includes an elongate, flexible probe having a channel running there through; a seton attached to a proximal end of the probe; and a wire located within the channel, and movable along the channel; wherein: the probe has a first stiffness and the wire has a second stiffness, the first stiffness being less than the second stiffness.
-
公开(公告)号：US20210147938A1
公开(公告)日：2021-05-20
申请号：US16874831
申请日：2020-05-15
发明人： Finbar Cotter , Christine Deguara , Colin Davis
IPC分类号： C12Q1/6883 , C12Q1/6886 , G01N33/564 , G01N33/68
摘要： The presence of certain auto antibodies and miRNAs indicates that a subject has endometriosis. The auto-antibodies recognise antigens listed in Table 1. The miRNAs are also listed in Table 1.
-
-
-
-
-
-
-
-
-
搜索结果
138 条记录 (耗时 0.026 秒)
